Pfizer’s Foes in Bench Trial Over Vyndamax Copies Down to Hikma

Pfizer Inc.'s agreements dropping two generic-drug makers from a patent case over copies of its blockbuster heart drug Vyndamax left Hikma Pharmaceuticals Plc the last remaining defendant for a bench trial slated to begin Monday.

Pfizer dismissed Cipla Ltd. in an order issued Monday by Judge Gregory B. Williams in the US District Court for the District of Delaware, three days after Williams signed off on the dismissal of Dexcel Pharma Technologies Ltd. from the consolidated case.

The pacts left the trial’s focus on whether Hikma’s proposed generic infringes US Patent No. 9,770,441, whose validity Hikma challenges. The patent ...